Cohance Lifesciences Ltd Q1 FY26 – 98.8x P/E, USFDA Love-Hate Story & Promoter Pledges 100% Like “EMI Pe Ghar”
1. At a Glance
Cohance Lifesciences (formerly Suven Pharma plus Advent ka masala) is the desi CDMO player trying to be the “Divi’s Labs 2.0” but priced like “Tesla PE ratio wala stock.” With ₹1,955 Cr sales, ₹352 Cr PAT, 28.8% OPM, but 98.8x P/E, the numbers scream “niche CDMO superstar,” but the market ka mood says “bhai, premium toh chahiye.” Add a spicy plot twist: 100% promoter pledge. Matlab ghar girvi, par party chalti rahegi.
2. Introduction
Hyderabad has two things in abundance: biryani and pharma companies. Cohance is the latter (unfortunately, no masala rice offering yet). Born out of Suven Pharma + Advent International’s checkbook, Cohance wants to be the contract research & manufacturing darling for Big Pharma. They’re already serving 14 of the top 20 pharma companies worldwide.
The pitch is sexy: “We’ll make your patented molecule in Phase-3, scale it up, and manufacture it for you at commercial stage.” It’s like being the reliable lab partner who never fails to bring distilled water while you do the viva.
But investors are left scratching heads: Sales growth 5-year = 7.5%, profit 5-year = -5.3% CAGR. Yet, market cap = ₹34,700 Cr. Why? Because “CDMO” is the new “AI”—everyone wants to own it without checking margins, execution, or the fact that USFDA inspectors are scarier than your tuition teacher with a cane.
3. Business Model – WTF Do They Even Do?
Cohance operates three main segments:
Pharma CDMO (72% of H1 FY25 revenue)
Custom synthesis for NCEs (new chemical entities).
Currently handling 12 commercial patented molecules and 7 in Phase-3.
But shipments backloaded in H1 FY25, revenue fell 4% YoY. Basically, “arre next quarter aa jaayega.”
Specialty Chemicals (6% vs 35% in FY22)
APIs like Gabapentin, Doxofylline, Rifapentine.
Down 76% YoY in H1 FY25—this segment is basically on ventilator.
Grew 28% YoY in H1 FY25—finally one subject they passed without cheating.
So overall, Cohance is not HUL-type FMCG. It’s like a backstage lab—innovators design, Cohance executes. But margin of error? Zero. Because if USFDA sneezes, share price catches pneumonia.
Question to readers: Agar 72% revenue ek hi segment se aa raha hai, aur woh bhi shipment delays dikha raha hai—should we call this “diversified” or “science student’s one-night-before-exam preparation”?
